NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=182857&from=3 CLASS PERIOD: Nov ...

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than Ja ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the prospects of its lead candidate, nimacimab, during the Class Period from November 4, 2024, to October 3, 2025 [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - The lawsuit claims that throughout the Class Period, the company misled investors about the potential success of nimacimab [2]. - Investors reportedly became aware of the misleading information on October 6, 2025, when Skye announced that nimacimab failed to meet its primary weight-loss endpoint in a Phase 2a trial, leading to a significant stock price drop of approximately 60%, closing at $1.90 [3]. Investor Information - Investors who purchased Skye securities during the Class Period have until January 16, 2026, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 4, 2024, and October 3, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2] - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Skye Bioscience's lead product candidate, nimacimab, reportedly did not meet the primary weight-loss endpoint in a Phase 2a study, leading to a significant drop in share price [4]. - Following the announcement of the study results, Skye's share price fell by 60%, decreasing from $4.75 to $1.90 per share [4]. Group 3: Company Background - Skye Bioscience is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [4]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [5]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [7].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the Class Period from November 4, 2024, to October 3, 2025 [1][3]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - Investors who purchased Skye securities during the Class Period have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. - The lawsuit claims that Skye failed to disclose that the efficacy of nimacimab was lower than previously represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Stock Performance - Following the announcement of topline data from a Phase 2a study on October 6, 2025, which revealed that the primary endpoint of an 8% weight loss difference compared to placebo was not met, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 [4].

Core Viewpoint - Halozyme Therapeutics, Inc. has entered into a global collaboration and license agreement with Skye Bioscience, Inc. to develop and commercialize higher-dose, subcutaneous administration strategies for nimacimab, targeting the obesity market [1] Group 1: Agreement Details - Skye Bioscience has licensed Halozyme's ENHANZE drug delivery technology to expand its application in the obesity market [1] - Skye plans to evaluate multiple dose-ranging strategies for nimacimab, including combinations with GLP-1 receptor agonists [2] - The agreement includes milestone payments from Skye to Halozyme based on the achievement of specific development and commercialization events [2] Group 2: Financial Terms and Future Plans - Halozyme will receive mid-single digit royalties on net sales of nimacimab developed with ENHANZE for a minimum of 10 years [3] - Skye intends to initiate a Phase 2b clinical trial for nimacimab with ENHANZE in obesity by mid-2026 [3] - In pre-market trading, HALO shares are priced at $70.46, reflecting a 0.21% increase, while SKYE shares are at $0.97, showing an 11.44% increase [3]

Core Insights - Halozyme Therapeutics and Skye Bioscience have entered a non-exclusive global collaboration to develop a subcutaneous formulation of nimacimab for obesity treatment, utilizing Halozyme's ENHANZE drug delivery technology [1][2] - The collaboration aims to evaluate higher doses of nimacimab through larger injection volumes, with Skye planning to initiate a Phase 2b clinical trial in mid-2026 [3] Group 1: Collaboration Details - Skye has licensed Halozyme's ENHANZE technology to support the development and commercialization of nimacimab, which is intended to enhance treatment options for obesity [1][2] - Skye will make milestone payments based on the achievement of specific development and commercialization events, while Halozyme will receive mid-single digit royalties on net sales of nimacimab for at least 10 years [2] Group 2: Market Potential and Strategy - The collaboration expands Halozyme's ENHANZE technology into the obesity market, which is identified as having significant long-term potential [2] - Halozyme's strategy focuses on driving sustainable royalty growth through new partnerships and innovations, reinforcing the scalability of ENHANZE across various therapeutic indications [2] Group 3: Clinical Development Plans - Skye plans to assess the combination of nimacimab with a GLP-1 receptor agonist in the upcoming Phase 2b clinical trial, which will evaluate multiple dose-ranging strategies [3][9] Group 4: Company Background - Halozyme is a biopharmaceutical company that develops solutions to improve patient experiences and outcomes, with a focus on drug delivery technologies [4][5] - The ENHANZE technology has been validated commercially and is licensed to numerous leading pharmaceutical companies, enhancing its market presence [5] Group 5: Future Innovations - Halozyme is also developing Hypercon™, a microparticle technology aimed at reducing injection volumes while expanding the scope of therapeutics that can be delivered subcutaneously [6] - The company is engaged in developing drug-device combination products to improve patient comfort and adherence [7]